Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial
- Resource Type
- Article
- Source
- In
The Lancet Oncology November 2021 22(11):1609-1617 - Subject
Primary Research Articles - Language
- ISSN
- 1470-2045